MedTrace Logo

AtorvaStatin Postpartum and Reduction of Cardiovascular risK

NCT06632379 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2025-10-17

No results posted yet for this study

Summary

The objective is to conduct a double-blinded randomized controlled trial of atorvastatin vs. placebo among postpartum individuals with hypertensive disorders of pregnancy, to improve cardiovascular risk score postpartum. For this, 76 individuals with hypertensive disorders of pregnancy (HDP) will be randomized to atorvastatin 10mg or placebo, which will be started in the postpartum period after cessation of breast feeding and continued for 3 months.

Conditions

  • Hypertensive Disorders of Pregnancy
  • Preeclampsia
  • Gestational Hypertension

Interventions

DRUG

Atorvastatin 10 mg

Participants will be assigned to 10 mg Atorvastatin

DRUG

Placebo

Participants will be assigned to identical appearing placebo

Sponsors & Collaborators

  • Ohio State University

    lead OTHER

Principal Investigators

  • Tracy C Bank, MD · Ohio State University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-03
Primary Completion
2026-09-15
Completion
2026-12-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06632379 on ClinicalTrials.gov